Foslevodopa/foscarbidopa subcutaneous infusion shows similar infusion site reaction severity score across range of infusion rates in patients with Parkinson’s disease
Objective: Characterize the relationship between foslevodopa/foscarbidopa infusion rate and infusion site reaction (ISR) score in patients with Parkinson’s disease (PD) Background: As PD progresses, motor…Levodopa-entacapone-carbidopa-infusion treatment in Parkinson’s disease: A six-month follow-up study
Objective: Objectives of this study were to evaluate changes in medication, adverse events and early discontinuations of levodopa-entacapone-carbidopa-intestinal-gel (LECIG) treatment in advanced Parkinson’s disease (PD).…Common oscillatory patterns between Parkinson’s disease and heroin dependent patients: a resting-state EEG study
Objective: We aimed to compare resting-state EEG oscillations between Parkinson’s disease (PD) patients during their ON and OFF Dopamine Replacement Therapy (DRT) states, heroin-dependent (HD)…Continuous algorithmic insights into PD motor symptoms and individual treatment response
Objective: To quantify the short-duration levodopa response using high resolution data derived from a wrist sensor and processed with advanced deep learning methods Background: The…Early versus late levodopa administration in Parkinson’s disease: Comparative study
Objective: To evaluate levodopa-sparing strategy in terms of motor decline and complications. Background: Levodopa remains the gold standard for treatment of Parkinson’s disease(PD), as it…The Short Duration Response and Long Duration Response to L-Dopa are Needed to Restore Vigor-Motivation Coupling in Parkinson Disease
Objective: To assess the relationship between the Short Duration Response (SDR) and Long Duration Response (LDR) to L-Dopa therapy in Parkinson disease (PD) and restoration…Pharmacokinetics, Safety and Tolerability of Foslevodopa/Foscarbidopa Following Continuous Subcutaneous Infusion to Arm, Thigh and Flank compared to Abdomen in Parkinson’s Disease Patients
Objective: To characterize safety/tolerability and pharmacokinetics (PK) of levodopa (LD) and carbidopa (CD) after delivery of foslevodopa/foscarbidopa in Parkinson’s disease (PD) patients at 4 different…Testing the applicability of the dysarthria analyzer to detect levodopa effects on speech in a German cohort of people with Parkinson’s disease
Objective: To test the applicability of “the dysarthria analyzer” in a levodopa challenge test to determine short term effects of levodopa on acoustic speech parameters.…Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for patients with Parkinson’s disease and motor fluctuations: Results from the Phase 3 randomized, active-controlled BouNDless study
Objective: Determine the efficacy, safety, and tolerability of ND0612 versus oral immediate-release levodopa/carbidopa (IR-LD/CD) in people with Parkinson’s disease (PwP) experiencing motor fluctuations. Background: ND0612…Dietary protein redistribution influences the efficacy of levodopa/carbidopa intestinal gel (LCIG) infusion
Objective: To compare levodopa/carbidopa intestinal gel (LCIG) with equally distributed dietary protein (Diet_EDP) versus restricted to twice daily (Diet_RP) and Mediterranean diet (Diet_M). Background: Levodopa…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 57
- Next Page »